We aim to be the leading specialty pharmaceutical group to improve the quality of human life
Investor Relations
Corporate Information
Financial Information
Stock Information
Newsroom
Webcasting
Information Request

Email This Print This Financial Ratios

Period
EPS (SGD)
(Earnings/Latest No. Of Shares)
NAV (SGD)
(Shareholders' Equity/Latest No. Of Shares)
Price Earnings Ratio (PER)
(Price/EPS)
Price/Revenue
(Price x Current No. Of Shares/Revenue)
Net Earnings Margin
(Net Earnings/Revenue)
Revenue Growth
((Current Year Revenue - Last Year Revenue) / Last Year Revenue)
Net Earnings Growth
((Current Year Earnings - Last Year Earnings) / Last Year Earnings)
Return On Asset (ROA)
(Net Earnings/Total Assets)
Return On Equity (ROE)
(Net Earnings/Equity)
Current Ratio
(Current Assets/Current Liabilities)
Full Year
Dec 2007
$0.02372
$0.3091
26.77
3.132
11.698 %
60.676 %
n.a.
5.254 %
7.674 %
2.173
Full Year
Dec 2006
$0.03426
$0.2978
18.53
4.981
27.146 %
-9.260 %
n.a.
9.992 %
11.503 %
3.117
Full Year
Dec 2005
$0.03619
$0.1393
17.55
3.778
26.024 %
59.181 %
21.336 %
22.804 %
25.974 %
6.188

Notes
  1. Adjusted Fundamental Data is data that is adjusted for share splits, bonus issues, share consolidations, rights issues and other changes in share capital (such as placement shares). The latest number of shares is used to calculate these adjusted ratios and is applied right across all the full year results. ShareInvestor updates the total number of shares in issue on a best effort basis.

  2. Share splits, bonus issues, share consolidations and rights issues are updated on the ex-date whereas other changes in share capital are updated within 7 working days of the release of the company's latest Results Announcement.